[Guidelines on diagnosis and treatment of pulmonary arterial hypertension].

[1]  K. Meyer,et al.  Bronchoalveolar lavage as a diagnostic tool. , 2007, Seminars in respiratory and critical care medicine.

[2]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[3]  S. Rich,et al.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[4]  D. Mccrory,et al.  Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .

[5]  M. Humbert,et al.  Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. , 2004, AJR. American journal of roentgenology.

[6]  M. Humbert,et al.  Pathologic assessment of vasculopathies in pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[7]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[8]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[9]  P. Corris,et al.  Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[10]  A. Fishman.  Primary pulmonary arterial hypertension: a look back. , 2004, Journal of the American College of Cardiology.

[11]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[12]  A. Torbicki,et al.  End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.

[13]  R. Naeije,et al.  End points in pulmonary arterial hypertension: the way forward , 2004, European Respiratory Journal.

[14]  M. Humbert,et al.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.

[15]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[16]  R. D. du Bois,et al.  Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. , 2004, Rheumatology.

[17]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[18]  A. Branzi,et al.  The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[19]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[20]  H. Kauczor,et al.  Assessment of pulmonary hypertension by CT and MR imaging , 2004, European Radiology.

[21]  G. Simonneau,et al.  [Pulmonary hypertension: CT findings in pulmonary veno-occlusive disease]. , 2003, Journal de radiologie.

[22]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[23]  S. Archer,et al.  Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.

[24]  M. Mcgoon,et al.  Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. , 2003, Mayo Clinic proceedings.

[25]  A. Torbicki,et al.  Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.

[26]  M. Hoeper,et al.  Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.

[27]  W. Seeger,et al.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[28]  D. Badesch,et al.  Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.

[29]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[30]  A. Branzi,et al.  Women and pulmonary arterial hypertension , 2003 .

[31]  A. Parkhomenko,et al.  Management of grown up congenital heart disease. , 2003, European heart journal.

[32]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[33]  G. Funk,et al.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.

[34]  A. Torbicki,et al.  Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[35]  W. Seeger,et al.  Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[36]  R. Barst,et al.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[37]  J. Newman,et al.  Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.

[38]  A. Branzi,et al.  Effects of sildenafil on growth and viability of cultured human pulmonary artery smooth muscle cells , 2003 .

[39]  P. Arbogast,et al.  Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. , 2003, American journal of respiratory and critical care medicine.

[40]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.

[41]  P. Thistlethwaite,et al.  Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.

[42]  S. Rich,et al.  Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.

[43]  T. Shim,et al.  Clinical Manifestations of Pulmonary Infection Due to Rapidly Growing Nontuberculous Mycobacteri , 2003 .

[44]  A. Branzi,et al.  Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[45]  S. Chuncharunee,et al.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. , 2003, International journal of hematology.

[46]  D. Blondheim,et al.  Expert consensus document on management of cardiovascular diseases during pregnancy. , 2003, European heart journal.

[47]  D. Badesch,et al.  Pulmonary hypertension associated with connective tissue disease. , 2002, Progress in cardiovascular diseases.

[48]  A. Branzi,et al.  The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.

[49]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[50]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[51]  R. Barst,et al.  Eisenmenger's syndrome: current management. , 2002, Progress in cardiovascular diseases.

[52]  E. Trulock,et al.  The registry of the international society for heart and lung transplantation: nineteenth official report-2002. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[53]  I. Khan,et al.  Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease , 2002, Angiology.

[54]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[55]  J. Greenfield,et al.  Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. , 2002, Chest.

[56]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[57]  C. Lavie,et al.  Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. , 2002, Circulation.

[58]  R. Hetzer,et al.  Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.

[59]  M. Humbert,et al.  Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis , 2002, European Respiratory Journal.

[60]  S. Rich,et al.  Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.

[61]  G. Simonneau,et al.  New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[62]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[63]  R. Barst,et al.  Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension , 2002 .

[64]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[65]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[66]  G. Verleden,et al.  Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.

[67]  M. Krowka.  Hepatopulmonary syndrome and portopulmonary hypertension , 2001, Current treatment options in cardiovascular medicine.

[68]  R. Barst,et al.  Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. , 2002, Chest.

[69]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[70]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[71]  Arthur E. Weyman,et al.  Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects , 2001, Circulation.

[72]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[73]  J. Sandoval,et al.  Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. , 2001, American journal of respiratory and critical care medicine.

[74]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[75]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[76]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[77]  E. Stork,et al.  Persistent pulmonary hypertension of the newborn. Rational therapy based on pathophysiology. , 2001, Clinics in perinatology.

[78]  A. Oberg,et al.  Unexplained pulmonary hypertension in chronic myeloproliferative disorders. , 2001, Chest.

[79]  J. Sandoval,et al.  Atrial septostomy for pulmonary hypertension. , 2001, Clinics in chest medicine.

[80]  R. Naeije,et al.  Medical therapy of pulmonary hypertension. Conventional therapies. , 2001, Clinics in chest medicine.

[81]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[82]  B. Winters,et al.  Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[83]  W F Walsh,et al.  Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. , 2001, The New England journal of medicine.

[84]  M. Katayama,et al.  [Pulmonary hypertension in patients with connective tissue diseases]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[85]  M. Rubenfire,et al.  Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.

[86]  Jürg Reichen,et al.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.

[87]  C. Denton,et al.  Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. , 2001, Rheumatology.

[88]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[89]  D. Badesch,et al.  Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[90]  M. Stewart,et al.  Group support for couples coping with a cardiac condition. , 2001, Journal of advanced nursing.

[91]  N. Galiè.  Do we need controlled clinical trials in pulmonary arterial hypertension? , 2001, The European respiratory journal.

[92]  R. Trembath,et al.  Primary pulmonary hypertension: the pressure rises for a gene , 2000, Journal of clinical pathology.

[93]  E. Ely,et al.  Pulmonary veno-occlusive disease: a case series and new observations. , 2000, Chest.

[94]  M. Gatzoulis,et al.  Sildenafil in primary pulmonary hypertension. , 2000, The New England journal of medicine.

[95]  R. Hetzer,et al.  [Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension]]. , 2000, Zeitschrift fur Kardiologie.

[96]  H. Farber,et al.  Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.

[97]  I. Khan,et al.  HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.

[98]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[99]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[100]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[101]  A. Magee,et al.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension , 2000, Heart.

[102]  R. Wiesner,et al.  Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[103]  M. Hoeper,et al.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.

[104]  J. Thumboo,et al.  Primary and secondary pulmonary hypertension in systemic lupus erythematosus , 2000, Lupus.

[105]  Adrian M Heilbut,et al.  Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.

[106]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[107]  M. Keszler,et al.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.

[108]  L. Hillis,et al.  Congenital heart disease in adults : Second of two parts , 2000 .

[109]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[110]  L. Hillis,et al.  Congenital heart disease in adults: First of two parts , 2000 .

[111]  B. Groves,et al.  Hyperuricemia in severe pulmonary hypertension. , 2000, Chest.

[112]  R. Lark,et al.  LOW-DOSE NITRIC OXIDE THERAPY FOR PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN , 2000 .

[113]  Inda,et al.  A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .

[114]  R A Nishimura,et al.  Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. , 2000, Mayo Clinic proceedings.

[115]  W. Seeger,et al.  A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[116]  J. Loyd,et al.  Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. , 2000, Chest.

[117]  L. Rubin,et al.  Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. , 1999, Chest.

[118]  J. Findlay,et al.  Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[119]  R. Wiesner,et al.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.

[120]  W. Seeger,et al.  Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[121]  P. Lange,et al.  Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects , 1999, Heart.

[122]  A. Chaouat,et al.  Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.

[123]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[124]  Thomas Albrecht,et al.  Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent , 1999, The Lancet.

[125]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[126]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[127]  P. Flemming,et al.  Pulmonary Hypertension after Splenectomy? , 1999, Annals of Internal Medicine.

[128]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[129]  J. Roos‐Hesselink,et al.  [Eisenmenger syndrome in adults]. , 1999, Nederlands tijdschrift voor geneeskunde.

[130]  M. Humbert,et al.  Treatment of pulmonary hypertension secondary to connective tissue diseases , 1999, Thorax.

[131]  M. Humbert,et al.  Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. , 1999, The European respiratory journal.

[132]  P. Presbitero,et al.  Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[133]  R. Naeije,et al.  False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. , 1998, European Respiratory Journal.

[134]  S. Rybalkin,et al.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[135]  M. Humbert,et al.  High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. , 1998, AJR. American journal of roentgenology.

[136]  J. Orens,et al.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.

[137]  J. Somerville,et al.  Small ventricular septal defects in adults. , 1998, European heart journal.

[138]  N. Voelkel,et al.  Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.

[139]  S. Rich,et al.  The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. , 1998, Chest.

[140]  A. Branzi,et al.  Primary Pulmonary Hypertension , 1998 .

[141]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[142]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[143]  J. Sandoval,et al.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.

[144]  J. W. Miller,et al.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.

[145]  O. Hess,et al.  Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.

[146]  J B Seward,et al.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[147]  M. Humbert,et al.  Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.

[148]  M. Humbert,et al.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[149]  Y. Kawaguchi,et al.  Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. , 1998, Biochemical and biophysical research communications.

[150]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[151]  C. Howell,et al.  Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.

[152]  T. Higenbottam,et al.  Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost , 1998, Heart.

[153]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[154]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[155]  T. Bashore,et al.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. , 1998, Chest.

[156]  R. Barst,et al.  Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. , 1997, Circulation.

[157]  C. Howell,et al.  Distinctive clinical features of portopulmonary hypertension. , 1997, Chest.

[158]  F. Martinez,et al.  Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. , 1997, AJR. American journal of roentgenology.

[159]  H P Gurtner,et al.  The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. , 1997, Chest.

[160]  G. Koch,et al.  Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension , 1997 .

[161]  R. Speich,et al.  HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.

[162]  C. Howell,et al.  Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[163]  A. Wells,et al.  Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. , 1997, British journal of rheumatology.

[164]  E. Beutler,et al.  Pulmonary Hypertension Developing after Alglucerase Therapy in Two Patients with Type 1 Gaucher Disease Complicated by the Hepatopulmonary Syndrome , 1996, Annals of Internal Medicine.

[165]  J. Seward,et al.  Frequency of Doppler measurable pulmonary artery pressures. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[166]  A J Tajik,et al.  Doppler echocardiographic index for assessment of global right ventricular function. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[167]  S. Swensen,et al.  Pulmonary venoocclusive disease: CT findings in eight patients. , 1996, AJR. American journal of roentgenology.

[168]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[169]  G. Simonneau,et al.  Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. , 1996, Circulation.

[170]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[171]  E. Trulock,et al.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[172]  J. Polson,et al.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.

[173]  K. Morris,et al.  Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.

[174]  S. Rich,et al.  Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. , 1995, Journal of the American College of Cardiology.

[175]  C. Benjamin,et al.  Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[176]  R. Sanson-Fisher,et al.  Breaking bad news: consensus guidelines for medical practitioners. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  O. Alfieri,et al.  [Pulmonary thromboendarterectomy in the surgical treatment of chronic thromboembolic pulmonary hypertension. First Italian experience]. , 1995, Cardiologia.

[178]  M. Mcgoon.  Medical treatment of pulmonary hypertension. , 1995, Cardiologia.

[179]  K. Stenmark,et al.  Persistent pulmonary hypertension of the newborn. , 1995, American journal of respiratory and critical care medicine.

[180]  D. Mitchell,et al.  AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.

[181]  J. Sandoval,et al.  Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.

[182]  J. Golden,et al.  Do patients with primary pulmonary hypertension develop extensive central thrombi? , 1995, Circulation.

[183]  A. Branzi,et al.  Role of pharmacologic tests in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[184]  G. Simonneau,et al.  Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.

[185]  E. Wouters,et al.  The International Primary Pulmonary Hypertension Study (IPPHS). , 1994, Chest.

[186]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[187]  I. Frank,et al.  Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. , 1994, Chest.

[188]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[189]  S. Rich,et al.  Short-term effectiveness of nifedipine in secondary pulmonary hypertension. , 1993, The American journal of cardiology.

[190]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[191]  S. Rich,et al.  Successful management of labor and delivery in primary pulmonary hypertension. , 1993, The American journal of cardiology.

[192]  R. R. Wolfe,et al.  Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.

[193]  G. Gray,et al.  In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. , 1993, Journal of cardiovascular pharmacology.

[194]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[195]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[196]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[197]  S. Rich,et al.  High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. , 1991, Journal of the American College of Cardiology.

[198]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[199]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[200]  A. Hadengue,et al.  Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. , 1991, Gastroenterology.

[201]  D. Moodie,et al.  Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.

[202]  G. Lister.  Persistent Pulmonary Hypertension of the Newborn , 1991, International Journal of Technology Assessment in Health Care.

[203]  J. Hageman,et al.  National survey of diagnosis and management of persistent pulmonary hypertension of the newborn. , 1990, Journal of perinatology : official journal of the California Perinatal Association.

[204]  A. Jaffe,et al.  Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. , 1990, Circulation.

[205]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[206]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[207]  N. Reichek,et al.  Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. , 1989, Circulation.

[208]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[209]  J. Rouleau,et al.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[210]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[211]  D. G. Ritter,et al.  Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. , 1987, Circulation.

[212]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[213]  B. Brundage,et al.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.

[214]  B. Brundage,et al.  Antinuclear antibodies in primary pulmonary hypertension. , 1986, Journal of the American College of Cardiology.

[215]  C. Oakley,et al.  Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.

[216]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[217]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[218]  G. Hutchins,et al.  Primary pulmonary hypertension and cirrhosis: are they related? , 2015, The American review of respiratory disease.

[219]  D. Nelson,et al.  Peripartum Heart Failure Due to Primary Pulmonary Hypertension , 1983, Obstetrics and gynecology.

[220]  B. Magnani,et al.  [Precapillary pulmonary hypertension: effect of Captopril]. , 1982, Giornale italiano di cardiologia.

[221]  R. Niedermann,et al.  Plexogenic pulmonary arteriopathy and liver cirrhosis. , 1980, Thorax.

[222]  D. Dhumeaux,et al.  Pulmonary hypertension complicating portal hypertension. , 1979, The American review of respiratory disease.

[223]  D. Dhumeaux,et al.  Pulmonary hypertension complicating portal hypertension. , 1979, The American review of respiratory disease.

[224]  J. Ochsner,et al.  Congenital Heart Disease in Adults , 1967, Southern medical journal.

[225]  A. Rudolph,et al.  The natural history of ventricular septal defects in infancy. , 1965, The American journal of cardiology.

[226]  W. Austen,et al.  EXPERIMENTAL STUDIES OF THE SURGICAL TREATMENT OF PRIMARY PULMONARY HYPERTENSION. , 1964, The Journal of thoracic and cardiovascular surgery.

[227]  E. Besterman.  ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION , 1961, British heart journal.

[228]  P. Wood.  PULMONARY HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOCONSTRICTIVE FACTOR* , 1958, British heart journal.